6th Annual MarketsandMarkets Neuroscience R&D Technologies Conference

WHAT TO EXPECT

Human iPSCs-derived Models in Neuroscience Researce
Neurodegeneration and Novel Translational Approaches
Therapeutic Antibodies for Neurodegenerative disorders
Disease Modelling and Drug Discovery
Role of Genetics and epigenetics in Neurodegeneration
Inclusion of AI and digital biomarkers in neuropathology
Emerging optogenetics tools: Studying Synaptic Plasticity
Neural Implants to treat Neurological Conditions
Neuromodulation and Brain Stimulation Techniques

To share and exchange the recent trends and technologies in neuroscience R&D.
Participate in discussions with experts on how technology implementation can be improved.
To better understand neurological factors that will help in drug designing.
Discover how AI and big data advancements is boosting neuroscience developments.
Discover the various issues and challenges coming up in neuroscience research.
Gain Knowledge on the progress of neurodegenerative disorders and their possible treatments.
Opportunity for networking with professionals, delegates, and speakers.

Designations:

CEO
CSO
CMO
COO
President
Vice President
Director
Head of Department
Executive leader
Senior Manager
Manager
Principle Scientist
Scientist
Neuroscientist
Professor
Associate Professor
Lecturer
Researcher

Working in the department:

Neuroscience/CNS drug discovery
Pre-clinical research
Neurobiology
Neurotechnology
Neuroinflammation
Neuroimmunology
Neurodegenerative diseases
Translational Neuroscience
Neuropharmacology
Neuroimaging /Translational Imaging
AI and Big data in neuroscience
Computational Neuroscience
Neural Engineering
Neurophysiology

CONFERENCE AGENDA

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
Systemic inflammation induced by lipopolysaccharide modulates Alzheimer’s disease progression Marie Christine Pardon, Assistant Professor in Translational Neuroscience, University of Nottingham	09:00 - 09:30
NEURODEGENERATION AND NOVEL THERAPEUTICS
Neuroprotective therapeutics: from monomodal to multimodal strategies Alan Palmer, Chief Executive Officer, Elixa MediScience, UK	09:30 - 10:00
Parkinson’s disease : alpha-synuclein toxicity and spreading, in vitro and in vivo models. Dr. Noelle Callizot, Chief Scientific Officer, Neuro-Sys	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
Patient-Led Discovery of Disease-Relevant Antibodies and Targets Paulina Kolasinska-Zwierz, Principal Scientist, Alchemab Therapeutics	11:15 - 11:45
Alzheimer’s Diseases: Translational Models and Brain-on-Chip innovations Dr. Jerome Bernard, Chief Business Officer, ETAP-Lab	11:45 - 12:15
TRP channels in glia: therapeutic potential? Mark Dallus, Professor in cellular neuroscience, University of Reading	12:15 - 12:45
Solution Provider Presentation	12:45 - 13:15
Lunch and Poster Presentation \| One-to-One Networking Meetings	13:15 - 14:15
MODELLING NEUROLOGICAL DISEASES USING IPSC-DERIVED NEURAL CELLS
Use of human stem cell models of neurological disease to advance drug discovery Clare Jones, Chief Scientific Officer, Talisman therapeutics	14:15 - 14:45
Enabling precision medicine using human iPSC models and clinical research Zameel Cader, Professor of Neuroscience and Neurology, University of Oxford	14:45 - 15:15
Cutting-edge iPSC platform at UCB for neurology indications Martine Geraerts, Director Cell biology, In-vitro Pharmacology, UCB Pharma	15:15 - 15:45
Evening Refreshments and Poster Presentation \| One-to-One Networking Meetings	15:45 - 16:30
Human neuronal networks on micro-electrode arrays are a robust tool to study disease phenotype in vitro Monica Frega, Assistant Professor, University of Twente	16:30 - 17:00
Panel Discussion: Experimental models in vitro: barriers and challenges to reproduce the complexity of the brain. Marie Christine Pardon, Assistant Professor in Translational Neuroscience, University of Nottingham Clare Jones, Chief Scientific Officer, Talisman therapeutics Monica Frega, Assistant Professor, University of Twente Alan Palmer, Chief Executive Officer, Elixa MediScience, UK	17:00 - 17:45
Closing Remarks from the Chairperson	17:45 - 17:50
Drinks Reception & Networking	17:50 - 17:50
End of Day 1	17:50 - 17:50

Registration	08:15 - 08:50
Welcome note from MarketsandMarkets	08:50 - 08:55
Opening Remarks from the Chairperson	08:55 - 09:00
Keynote Presentation	09:00 - 09:30
INCLUSION OF AI AND DIGITAL BIOMARKERS
Artificial intelligence – Recognizing hidden patterns in human brain	09:30 - 10:00
Solution Provider Presentation	10:00 - 10:30
Morning Refreshments and Poster Presentation \| One-to-One Networking Meetings	10:30 - 11:15
The challenge of privacy in AI models: Assessing the risk of Artificial Intelligence (AI), which uses multi-modal healthcare data, and how we can preserve privacy within them. Lewis Hotchkiss, Data Scientist, Neuroimaging Researcher, Dementia Platform UK	11:15 - 11:45
The future of neural implants to treat neurological conditions Patrick Degenaar, Professor in Neuroprosthetics, Newcastle University	11:45 - 12:15
Digital Biomarker Strategies for Successful Development of Neuroscience Targets Kiri Granger, Chief Scientific Officer, Monument Therapeutics	12:15 - 12:45
Lunch and Poster Presentation \| One-to-One Networking Meetings	12:45 - 13:45
NEUROMODULATION AND FUTURE DEVELOPMENTS IN NEUROSCIENCE R&D
Neuroengineering: the novel frontier for restoring neural functions Michela Chiappalone , Associate Professor, University of Genova	13:45 - 14:15
tVNS research in neurorehabilitation. Dr. Ali Ali, Senior Clinical Lecturer Cerebrovascular Disease, University of Sheffield	14:15 - 14:45
Panel Discussion: Ethical Dilemmas Surrounding Neuromodulation and Brain-Computer Interfaces (BCIs): A Deliberation on Principles and Practices Dr. Ali Ali, Senior Clinical Lecturer Cerebrovascular Disease, University of Sheffield	14:45 - 15:30
Closing Remarks from the Chairperson	15:30 - 15:35
End of the conference	15:35 - 15:35